We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$28.5B
AUM Growth
+$2.42B
(+9.3%)
Cap. Flow
+$581M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
19.66%
Holding
1,921
New
171
Increased
1,320
Reduced
356
Closed
71
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$111M |
| 2 |
VF Corp
VFC
|
+$73.4M |
| 3 |
Amazon
AMZN
|
+$71M |
| 4 |
Stanley Black & Decker
SWK
|
+$60.2M |
| 5 |
Tesla
TSLA
|
+$46.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Target
TGT
|
+$158M |
| 2 |
Apple
AAPL
|
+$130M |
| 3 |
Cardinal Health
CAH
|
+$43.7M |
| 4 |
Fortinet
FTNT
|
+$39.6M |
| 5 |
ExxonMobil
XOM
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.73% |
| 2 | Industrials | 12.07% |
| 3 | Consumer Staples | 11.64% |
| 4 | Healthcare | 11.12% |
| 5 | Financials | 10.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Sabre
SABR
$656M
| $319K | ﹤0.01% |
51,540
-2,347
| -4% | -$13.1K |
|
1202
Ultragenyx Pharmaceutical
RARE
$2.65B
| $318K | ﹤0.01% |
6,862
-145
| -2% | -$5.7K |
|
1203
Glaukos
GKOS
$9.02B
| $318K | ﹤0.01% |
7,278
+939
| +15% | +$46.3K |
|
|
B
1204
DELISTED
Barnes Group Inc.
B
| $318K | ﹤0.01% |
+7,775
| New | +$290K |
|
|
RVNC
1205
DELISTED
Revance Therapeutics, Inc.
RVNC
| $317K | ﹤0.01% |
17,193
+3,136
| +22% | +$71.7K |
|
1206
Robinhood
HOOD
$85.2B
| $316K | ﹤0.01% |
38,849
+4,981
| +15% | +$48.8K |
|
1207
Evertec
EVTC
$1.83B
| $316K | ﹤0.01% |
9,764
+1,069
| +12% | +$35.1K |
|
1208
Rapid7
RPD
$634M
| $316K | ﹤0.01% |
9,285
+1,025
| +12% | +$36.6K |
|
|
PRMW
1209
DELISTED
Primo Water Corporation
PRMW
| $315K | ﹤0.01% |
20,278
+2,905
| +17% | +$42.2K |
|
1210
Amdocs
DOX
$5.53B
| $315K | ﹤0.01% |
3,466
-381
| -10% | -$32.4K |
|
1211
Moelis & Co
MC
$4.98B
| $315K | ﹤0.01% |
8,203
+1,175
| +17% | +$47.7K |
|
1212
Cavco Industries
CVCO
$4.39B
| $314K | ﹤0.01% |
1,389
+183
| +15% | +$40.6K |
|
1213
Cushman & Wakefield Ltd
CWK
$2.98B
| $314K | ﹤0.01% |
25,207
+7,681
| +44% | +$88.8K |
|
1214
Edgewell Personal Care
EPC
$1.27B
| $314K | ﹤0.01% |
8,142
+1,051
| +15% | +$41.7K |
|
1215
Relay Therapeutics
RLAY
$4.02B
| $313K | ﹤0.01% |
20,950
+3,355
| +19% | +$64.2K |
|
1216
Post Holdings
POST
$4.12B
| $313K | ﹤0.01% |
3,466
+405
| +13% | +$36.1K |
|
1217
Integra LifeSciences
IART
$1.54B
| $313K | ﹤0.01% |
5,578
+449
| +9% | +$22.9K |
|
1218
SiTime
SITM
$16.6B
| $312K | ﹤0.01% |
3,075
+418
| +16% | +$39.5K |
|
1219
Crane NXT
CXT
$3.04B
| $312K | ﹤0.01% |
8,951
+1,068
| +14% | +$37.3K |
|
1220
CRISPR Therapeutics
CRSP
$4.58B
| $312K | ﹤0.01% |
7,663
-141
| -2% | -$7.48K |
|
1221
OneMain Financial
OMF
$6.9B
| $311K | ﹤0.01% |
9,339
+1,034
| +12% | +$36.7K |
|
1222
Minerals Technologies
MTX
$2.31B
| $311K | ﹤0.01% |
5,118
+657
| +15% | +$37.2K |
|
1223
Otter Tail
OTTR
$3.88B
| $311K | ﹤0.01% |
5,293
+759
| +17% | +$45.5K |
|
1224
Insulet
PODD
$11.3B
| $310K | ﹤0.01% |
1,053
-52
| -5% | -$14.3K |
|
|
KDNY
1225
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $309K | ﹤0.01% |
11,811
+1,023
| +9% | +$22.7K |
|
Similar funds
ProShare Advisors's Q4 2022 Portfolio in Review
As of Q4 2022, ProShare Advisors held 1,921 positions worth $28.5B, up 9.3% from $26.1B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
ProShare Advisors's Q4 2022 filing shows 171 new, 1,320 increased, 356 reduced and 71 closed positions. Its largest new stake was Rivian: 689,839 shares worth $12.7M. The largest sale was Target, an estimated $158M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.
- ProShare Advisors's largest Q4 2022 buy was Rivian: 689,839 shares worth $12.7M.
- ProShare Advisors added most to Microsoft in Q4 2022, an estimated $111M increase.
- ProShare Advisors's biggest Q4 2022 reduction was Apple, cutting an estimated $130M.
- ProShare Advisors fully exited Target in Q4 2022, selling an estimated $158M.
- ProShare Advisors's ten largest holdings make up 20% of its $28.5B portfolio in Q4 2022.
- ProShare Advisors opened 171 new positions and closed 71 in Q4 2022.
- ProShare Advisors's portfolio value rose 9.3% quarter-over-quarter to $28.5B.
Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.